Report Detail
Global Gabapentin Market Insights, Forecast to 2025
- RnM2652277 |
- 08 April, 2019 |
- Global |
- 125 Pages |
- QYResearch |
- Pharma & Healthcare
Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.
Gabapentin was originally marketed under the brand name Neurontin and since it became generic, it has been marketed under many other brand names. An extended-release formulation of gabapentin for once-daily administration was introduced in 2011 for postherpetic neuralgia under the brand name Gralise.
Gabapentin is used primarily to treat seizures and neuropathic pain. It is also commonly prescribed for many off-label uses, such as treatment of anxiety disorders, insomnia, and bipolar disorder. There are, however, concerns regarding the quality of the trials conducted and evidence for some such uses, especially in the case of its use as a mood stabilizer in bipolar disorder.
The global Gabapentin market is valued at 1430 million US$ in 2018 and will reach 1630 million US$ by the end of 2025, growing at a CAGR of 1.8% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Gabapentin market based on company, product type, end user and key regions.
This report studies the global market size of Gabapentin in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Gabapentin in these regions.
This research report categorizes the global Gabapentin market by top players/brands, region, type and end user. This report also studies the global Gabapentin market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Depomed
TEVA
Mylan
Arbor Pharma
Novartis
Apotex
Sun Pharmaceutical
Aurobindo Pharma
Intas
Amneal
Marksans Pharma
Glenmark
Alkem
Jiangsu Enhua
Jiangsu Hengrui
Sailike
Market size by Product
Capsule
Tablet
Market size by End User
Epilepsy
Neuropathic Pain
Restless Legs Syndrome
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Gabapentin market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Gabapentin market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Gabapentin companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Gabapentin submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Gabapentin are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (M Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Gabapentin market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Gabapentin Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Gabapentin Market Size Growth Rate by Product
- 1.4.2 Capsule
- 1.4.3 Tablet
- 1.5 Market by End User
- 1.5.1 Global Gabapentin Market Size Growth Rate by End User
- 1.5.2 Epilepsy
- 1.5.3 Neuropathic Pain
- 1.5.4 Restless Legs Syndrome
- 1.5.5 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Gabapentin Market Size
- 2.1.1 Global Gabapentin Revenue 2014-2025
- 2.1.2 Global Gabapentin Sales 2014-2025
- 2.2 Gabapentin Growth Rate by Regions
- 2.2.1 Global Gabapentin Sales by Regions
- 2.2.2 Global Gabapentin Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Gabapentin Sales by Manufacturers
- 3.1.1 Gabapentin Sales by Manufacturers
- 3.1.2 Gabapentin Sales Market Share by Manufacturers
- 3.1.3 Global Gabapentin Market Concentration Ratio (CR5 and HHI)
- 3.2 Gabapentin Revenue by Manufacturers
- 3.2.1 Gabapentin Revenue by Manufacturers (2014-2019)
- 3.2.2 Gabapentin Revenue Share by Manufacturers (2014-2019)
- 3.3 Gabapentin Price by Manufacturers
- 3.4 Gabapentin Manufacturing Base Distribution, Product Types
- 3.4.1 Gabapentin Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Gabapentin Product Type
- 3.4.3 Date of International Manufacturers Enter into Gabapentin Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Gabapentin Sales by Product
- 4.2 Global Gabapentin Revenue by Product
- 4.3 Gabapentin Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Gabapentin Breakdown Data by End User
6 North America
- 6.1 North America Gabapentin by Countries
- 6.1.1 North America Gabapentin Sales by Countries
- 6.1.2 North America Gabapentin Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Gabapentin by Product
- 6.3 North America Gabapentin by End User
7 Europe
- 7.1 Europe Gabapentin by Countries
- 7.1.1 Europe Gabapentin Sales by Countries
- 7.1.2 Europe Gabapentin Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Gabapentin by Product
- 7.3 Europe Gabapentin by End User
8 Asia Pacific
- 8.1 Asia Pacific Gabapentin by Countries
- 8.1.1 Asia Pacific Gabapentin Sales by Countries
- 8.1.2 Asia Pacific Gabapentin Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Gabapentin by Product
- 8.3 Asia Pacific Gabapentin by End User
9 Central & South America
- 9.1 Central & South America Gabapentin by Countries
- 9.1.1 Central & South America Gabapentin Sales by Countries
- 9.1.2 Central & South America Gabapentin Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Gabapentin by Product
- 9.3 Central & South America Gabapentin by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Gabapentin by Countries
- 10.1.1 Middle East and Africa Gabapentin Sales by Countries
- 10.1.2 Middle East and Africa Gabapentin Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Gabapentin by Product
- 10.3 Middle East and Africa Gabapentin by End User
11 Company Profiles
- 11.1 Pfizer
- 11.1.1 Pfizer Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Pfizer Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Pfizer Gabapentin Products Offered
- 11.1.5 Pfizer Recent Development
- 11.2 Depomed
- 11.2.1 Depomed Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Depomed Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Depomed Gabapentin Products Offered
- 11.2.5 Depomed Recent Development
- 11.3 TEVA
- 11.3.1 TEVA Company Details
- 11.3.2 Company Business Overview
- 11.3.3 TEVA Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 TEVA Gabapentin Products Offered
- 11.3.5 TEVA Recent Development
- 11.4 Mylan
- 11.4.1 Mylan Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Mylan Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Mylan Gabapentin Products Offered
- 11.4.5 Mylan Recent Development
- 11.5 Arbor Pharma
- 11.5.1 Arbor Pharma Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Arbor Pharma Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Arbor Pharma Gabapentin Products Offered
- 11.5.5 Arbor Pharma Recent Development
- 11.6 Novartis
- 11.6.1 Novartis Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Novartis Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Novartis Gabapentin Products Offered
- 11.6.5 Novartis Recent Development
- 11.7 Apotex
- 11.7.1 Apotex Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Apotex Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Apotex Gabapentin Products Offered
- 11.7.5 Apotex Recent Development
- 11.8 Sun Pharmaceutical
- 11.8.1 Sun Pharmaceutical Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Sun Pharmaceutical Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Sun Pharmaceutical Gabapentin Products Offered
- 11.8.5 Sun Pharmaceutical Recent Development
- 11.9 Aurobindo Pharma
- 11.9.1 Aurobindo Pharma Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Aurobindo Pharma Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Aurobindo Pharma Gabapentin Products Offered
- 11.9.5 Aurobindo Pharma Recent Development
- 11.10 Intas
- 11.10.1 Intas Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Intas Gabapentin Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Intas Gabapentin Products Offered
- 11.10.5 Intas Recent Development
- 11.11 Amneal
- 11.12 Marksans Pharma
- 11.13 Glenmark
- 11.14 Alkem
- 11.15 Jiangsu Enhua
- 11.16 Jiangsu Hengrui
- 11.17 Sailike
12 Future Forecast
- 12.1 Gabapentin Market Forecast by Regions
- 12.1.1 Global Gabapentin Sales Forecast by Regions 2019-2025
- 12.1.2 Global Gabapentin Revenue Forecast by Regions 2019-2025
- 12.2 Gabapentin Market Forecast by Product
- 12.2.1 Global Gabapentin Sales Forecast by Product 2019-2025
- 12.2.2 Global Gabapentin Revenue Forecast by Product 2019-2025
- 12.3 Gabapentin Market Forecast by End User
- 12.4 North America Gabapentin Forecast
- 12.5 Europe Gabapentin Forecast
- 12.6 Asia Pacific Gabapentin Forecast
- 12.7 Central & South America Gabapentin Forecast
- 12.8 Middle East and Africa Gabapentin Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Gabapentin Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Gabapentin . Industry analysis & Market Report on Gabapentin is a syndicated market report, published as Global Gabapentin Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Gabapentin market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
